Kamau Stem Cell Therapy Nula-cel Wins FDA Advanced Therapy Designation: All 3 Sickle Cell Patients Transfusion-Free
Kamau Therapeutics of South San Francisco, California, announced on November 12 that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nula-cel, its investigational stem cell medicine for sickle cell disease. The designation is based on preliminary clinical evidence from the ongoing Phase 1/2 RESTORE trial, and nula-cel also holds FDA Fast Track and Orphan Drug designations.
In RESTORE, all three patients treated with the optimized manufacturing process achieved transfusion independence with no vaso-occlusive events. The two patients with more than six months of follow-up have sickle hemoglobin below 20%, under the 30% threshold targeted for stroke prevention, with a predominantly adult hemoglobin profile.
RMAT designation is granted when preliminary clinical evidence indicates that a regenerative medicine therapy has the potential to address unmet medical needs in a serious condition. Designated therapies receive early, frequent FDA engagement and may be eligible for priority review and accelerated approval.
Kamau Chief Executive Officer Vali Barsan said pain crises matter, but between them sickled cells continue damaging the body, which is why guidelines call for exchange transfusions to keep sickle hemoglobin below 30% to prevent stroke, and that nula-cel was designed to correct the root cause of sickle cell disease in a single treatment. Chief Medical Officer Jacob Garcia said the company plans to request the comprehensive multidisciplinary RMAT meeting the agency recommended, to align on the path to a registrational dataset including the potential for priority review and endpoints for accelerated approval, and expects to share additional interim efficacy data from RESTORE later this year.
Nula-cel is an investigational stem cell medicine for sickle cell disease. Rather than inducing fetal hemoglobin to compensate for the disease, it is designed to correct the sickle mutation itself, converting it to the normal adult beta-globin sequence. Using ex vivo homology-directed repair (HDR), Kamau engineers a patient's own long-lived stem cells outside the body, verifying each cell product's quality, identity, potency and safety before it is returned to the patient. As these cells self-renew, a one-time treatment is designed to deliver durable, potentially lifelong benefit. The RESTORE trial is registered as NCT04819841.
Sickle cell disease is an inherited blood disorder affecting approximately 100,000 people in the United States and millions globally. A single mutation in the beta-globin gene produces sickle hemoglobin, which stiffens red cells and drives chronic hemolysis. Pain crises are the visible burden, while chronic organ damage, including stroke and injury to the kidneys, retinas and bones, accumulates silently between them, shortening U.S. life expectancy by decades.
Nula-cel remains investigational and is not approved; RMAT designation is not an approval, and its efficacy and safety must still be confirmed in larger trials. (Source: Kamau Therapeutics)
Source: Kamau Therapeutics
Published by GSM · USA (original Chinese edition)
Photo: 图：镰状细胞病患者血涂片，可见镰刀形红细胞。Prof. Osaro Erhabor 摄，Wikimedia Commons，CC0。 / Image: Blood film in sickle cell disease showing sickle-shaped red cells. By Prof. Osaro Erhabor, via Wikimedia Commons, CC0.
